2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150In combination, tesamorelin and ipamorelin represent a dual-pathway approach to modulating endogenous GH pulsatility, leveraging established physiological interactions between GHRH and ghrelin signaling.
While direct combination studies are limited, existing mechanistic and translational evidence supports further investigation of this pairing as a research model for coordinated GH axis regulation.
Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) composed of 44 amino acids, designed to stimulate endogenous, pulsatile growth hormone (GH) secretion from the anterior pituitary [1].
By binding to the GHRH receptor, tesamorelin activates cAMP-mediated signaling in somatotroph cells, promoting downstream increases in insulin-like growth factor-1 (IGF-1) while preserving normal feedback regulation [2].
Tesamorelin is a well-characterized tool for elucidating GHRH-driven regulation as both model organisms and clinical research have investigated for effects on [3]:
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively activates the ghrelin (GHS-R1a) receptor in the hypothalamus and pituitary [4].
Through this pathway, ipamorelin stimulates pulsatile growth hormone (GH) release without significantly increasing other pituitary hormones such as cortisol or prolactin.
In research settings, ipamorelin has been investigated for its high signaling specificity and favorable endocrine selectivity, making it a complementary agent to GHRH analogs when studying coordinated regulation of endogenous GH secretion.
The rationale for combining tesamorelin and ipamorelin is grounded in well-characterized physiological cross-talk between the GHRH and ghrelin/GHS signaling systems, which regulate the amplitude and timing of endogenous growth hormone (GH) pulses.
Rather than acting redundantly, these peptides engage distinct but convergent control pathways within the somatotropic axis.
Tesamorelin is a GHRH analog that activates the GHRH receptor on pituitary somatotrophs, while Ipamorelin is a selective ghrelin (GHS-R1a) receptor agonist.
GHS-R1a activation is typically associated with PLC-linked signaling, intracellular calcium mobilization, and enhanced somatotroph responsiveness [5].
Importantly, ghrelin/GHS signaling does not independently raise cAMP, but it can potentiate GHRH-driven cAMP responses when both receptors are engaged.
Direct clinical trials specifically evaluating tesamorelin combined with ipamorelin are limited. However, the broader literature provides several relevant lines of evidence:
Taken together, this data supports the potential of tesamorelin–ipamorelin synergy via coordinated engagement of complementary regulatory pathways, even though formal combination trials remain sparse.
From a research-design perspective, allocating a greater proportion of the total peptide mass to tesamorelin (7 mg) can be viewed as emphasizing primary drivers through the main GHRH pathway, which establishes pulse timing and baseline GH output.
Ipamorelin (3 mg) can then function as a selective amplifier, enhancing somatotroph responsiveness through GHS-R1a–mediated cross-talk without broadly activating appetite or stress-related endocrine pathways. This lower ghrelin receptor agonist to GHRH ratio is in agreement with the literature in terms of producing synergistic GH secretion effects [6].
Beyond this high-level rationale, optimal dosing ratios are not established in the open literature and should be regarded as empirical parameters rather than evidence-based standards.
References:
2 Halmos, G., Szabo, Z., Dobos, N., Juhasz, E. and Schally, A. V. (2025) Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev. Endocr. Metab. Disord., Springer Science and Business Media LLC 26, 343–352
3 Results from the 26-week Confirmatory, Phase 3 Trial of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV Patients with Excess Abdominal Fat: A Multicenter, Double-blind, Placebo-controlled Study with 404 Randomized Patients https://www.natap.org/2008/IAS/IAS_56.htm
4 Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., et al. (2020) Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl. Androl. Urol., AME Publishing Company 9, S149–S159
5 Mear, Y., Enjalbert, A. and Thirion, S. (2013) GHS-R1a constitutive activity and its physiological relevance. Front. Neurosci., Frontiers Media SA 7, 87
6 Hataya, Y., Akamizu, T., Takaya, K., Kanamoto, N., Ariyasu, H., Saijo, M., et al. (2001) A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J. Clin. Endocrinol. Metab., The Endocrine Society 86, 4552
7 Cunha, S. R. and Mayo, K. E. (2002) Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3’,5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, The Endocrine Society 143, 4570–4582
8 Casanueva, F. F. and Dieguez, C. (1999) Growth hormone secretagogues: Physiological role and clinical utility. Trends Endocrinol. Metab., Elsevier BV 10, 30–38
9 Stanley, T. L., Chen, C. Y., Branch, K. L., Makimura, H. and Grinspoon, S. K. (2011) Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J. Clin. Endocrinol. Metab., The Endocrine Society 96, 150–158
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Tesamorelin + Ipamorelin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue. It is approved for treating HIV-associated lipodystrophy. It is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV.
Ipamorelin is a growth hormone secretagogue (GHS) from the peptidomimetic GHS family. In animal research, ipamorelin is described as a peripherally restricted ghrelin mimetic. The authors of that animal study suggested it may offer a novel approach for treating acute visceral and somatic pain. In a separate study, ipamorelin was one of the peptidomimetic GHS families from which the authors derived 4-fluorobenzoylated compounds for PET imaging of the ghrelin receptor.
In a human clinical trial of people with HIV on INSTI-based regimens, tesamorelin led to significant declines in visceral fat compared with placebo. The median change in visceral fat was -25 cm2 with tesamorelin versus 14 cm2 with placebo (P = 0.001). In the same population, tesamorelin had beneficial effects on body composition with no worsening of glycemic control. A human review concluded that tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects or perturbation of glucose.
In animal studies, ipamorelin is described as a peripherally restricted ghrelin mimetic and a selective ghrelin receptor agonist. In rats, ipamorelin was given intravenously to study visceral and somatic nociception. In animals, the anti-nociceptive effects of ipamorelin and HM01 were blocked by the ghrelin receptor antagonist H0900, indicating a ghrelin receptor-mediated mechanism. In the animal study, the authors suggest that this peripherally restricted ghrelin mimetic may offer a novel approach for treating acute visceral and somatic pain.
In a human clinical trial, Tesamorelin was described as well tolerated, with a similar frequency of adverse events, including hyperglycemia, between groups. A human review concluded that Tesamorelin, in HIV-associated lipodystrophy, was given without serious side effects or perturbation of glucose.
The provided facts do not mention FDA approval for ipamorelin. A review describes ipamorelin, a growth hormone axis secretagogue, as investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions. The same review's conclusion calls peptides such as ipamorelin experimental substances with poorly defined long-term risks. Growth hormone releasing peptides, the class ipamorelin belongs to, are listed on the World Anti-Doping Agency Prohibited List.
In a human clinical trial, tesamorelin was associated with a significant increase in lean body mass (MD=1.42 kg, 95% CI [1.13, 1.71]; P < 0.001) in adults with HIV. In a human clinical trial, tesamorelin increased IGF-1 levels, but these changes did not correlate with the summary regression change score or waist circumference.
A review describes Ipamorelin, a growth hormone axis secretagogue, as investigational, with an uncertain safety profile and product quality concerns. The same review concludes that peptides such as Ipamorelin remain experimental substances with poorly defined long-term risks, and that their use should be considered high-risk until longitudinal data are available. The review also notes that the largely unregulated supply chain for peptides such as Ipamorelin means products are often mislabeled or contaminated.
A review states that dedicated studies of tesamorelin, a growth hormone-releasing hormone analog, have shown promise in fatty liver disease (MASLD) among people with HIV. The same review concludes that tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects or perturbation of glucose.
In a fish study, ipamorelin (IPA) at 5 or 30 µg significantly elevated serum luteinizing hormone (LH) and 11-ketotestosterone (11-KT) compared with controls. The available findings concern 11-ketotestosterone, so they do not directly show a rise in testosterone. Fish treated with 30 µg of IPA also showed a significant elevation in androgen receptor protein expression.
In an observational analysis of the FAERS adverse event reporting database in humans, tesamorelin was one of ten drugs with significant overreporting of carpal tunnel syndrome. The reporting odds ratio for tesamorelin was 20.7, with a 95% confidence interval of 13.7 to 31.3. The same database analysis concluded that growth hormone (GH)-releasing factor analogs, a drug class that includes tesamorelin, were disproportionately associated with carpal tunnel syndrome.
In ferrets, ipamorelin was given intraperitoneally at 1-3 mg/kg 30 s before cisplatin (5 mg/kg, i.p.), with subsequent doses every 24 h, and behaviour was recorded for up to 72 h. In these ferret experiments, intraperitoneally administered ipamorelin had no effect on cisplatin-induced acute or delayed emesis. Ipamorelin inhibited cisplatin-induced weight loss on the last day of the delayed phase (48-72 h) by approximately 24 % in ferrets. The authors concluded that intraperitoneally administered ipamorelin had beneficial effects in alleviating cisplatin-induced weight loss during the delayed phase in ferrets.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.